Capula Management Ltd Purchases Shares of 14,647 Hims & Hers Health, Inc. (NYSE:HIMS)

Capula Management Ltd acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,647 shares of the company's stock, valued at approximately $354,000.

Several other hedge funds have also made changes to their positions in HIMS. SlateStone Wealth LLC grew its position in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares during the period. Harbour Investments Inc. boosted its holdings in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after acquiring an additional 833 shares in the last quarter. Stonekeep Investments LLC increased its stake in shares of Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock worth $410,000 after acquiring an additional 882 shares during the period. Finally, LPL Financial LLC raised its holdings in Hims & Hers Health by 1.0% during the fourth quarter. LPL Financial LLC now owns 97,958 shares of the company's stock worth $2,369,000 after purchasing an additional 980 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Ratings Changes

HIMS has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Piper Sandler raised their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Finally, Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $38.25.

Remove Ads

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the transaction, the chief financial officer now directly owns 118,077 shares in the company, valued at approximately $2,885,801.88. This represents a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 33,337 shares of Hims & Hers Health stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $27.32, for a total value of $910,766.84. Following the completion of the sale, the chief operating officer now owns 805,083 shares of the company's stock, valued at $21,994,867.56. This trade represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 835,884 shares of company stock worth $31,659,701. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Up 1.2 %

Shares of NYSE HIMS traded up $0.32 during trading on Friday, reaching $27.13. The company had a trading volume of 16,210,541 shares, compared to its average volume of 15,146,132. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The stock has a 50-day moving average price of $38.75 and a two-hundred day moving average price of $30.46. The stock has a market capitalization of $6.03 billion, a PE ratio of 61.66 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.